Patient and disease characteristics
| . | All patients . | Grouped by ANC <0.5 × 109/L at day 36∗ . | |
|---|---|---|---|
| No . | Yes . | ||
| No. of patients, N | 51 | 31 | 18 |
| Age, median y (range) | 3.7 (1.1-17.3) | 4.3 (1.6-17.1) | 3.5 (1.4-14.5) |
| Sex, Male/Female, n (%) | 38 (75)/13 (25) | 26 (84)/5 (16) | 10 (56)/8 (44) |
| ALL phenotype, n (%) | |||
| Pre-B-cell ALL | 43 (84) | 26 (84) | 17 (94) |
| T-cell ALL | 7 (14) | 4 (13) | 1 (6) |
| Other† | 1 (2) | 1 (3) | 0 (0) |
| Induction∗ , n (%) | |||
| Nonhigh-risk | 42 (82) | 27 (87) | 15 (83) |
| High-risk | 5 (10) | 4 (13) | 1 (6) |
| Other‡ | 4 (8) | 0 (0) | 2 (11) |
| Treating center, n (%) | |||
| Odense University Hospital | 15 (29) | 7 (23) | 7 (39) |
| Rigshospitalet, Copenhagen University Hospital | 33 (65) | 22 (71) | 10 (56) |
| Aarhus University Hospital | 3 (6) | 2 (6) | 1 (6) |
| . | All patients . | Grouped by ANC <0.5 × 109/L at day 36∗ . | |
|---|---|---|---|
| No . | Yes . | ||
| No. of patients, N | 51 | 31 | 18 |
| Age, median y (range) | 3.7 (1.1-17.3) | 4.3 (1.6-17.1) | 3.5 (1.4-14.5) |
| Sex, Male/Female, n (%) | 38 (75)/13 (25) | 26 (84)/5 (16) | 10 (56)/8 (44) |
| ALL phenotype, n (%) | |||
| Pre-B-cell ALL | 43 (84) | 26 (84) | 17 (94) |
| T-cell ALL | 7 (14) | 4 (13) | 1 (6) |
| Other† | 1 (2) | 1 (3) | 0 (0) |
| Induction∗ , n (%) | |||
| Nonhigh-risk | 42 (82) | 27 (87) | 15 (83) |
| High-risk | 5 (10) | 4 (13) | 1 (6) |
| Other‡ | 4 (8) | 0 (0) | 2 (11) |
| Treating center, n (%) | |||
| Odense University Hospital | 15 (29) | 7 (23) | 7 (39) |
| Rigshospitalet, Copenhagen University Hospital | 33 (65) | 22 (71) | 10 (56) |
| Aarhus University Hospital | 3 (6) | 2 (6) | 1 (6) |
Nordic Society of Paediatric Haematology and Oncology ALL-2008 induction includes IV vincristine at a 2 mg/m2 dose on days 1, 8, 15, 22, and 29, IV doxorubicin at 40 mg/m2 on days 1 and 22, and intrathecal methotrexate on days 1, 8, 15, and 29. High-risk induction included dexamethasone 10 mg/m2 per day on treatment days 1 to 21 and nonhigh-risk induction included prednisolone 60 mg/m2 per day on treatment days 1 to 28.
Blastic plasmacytoid dendritic cell acute leukemia treated with the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol.
Two patients started high-risk consolidation therapy before the end-of-induction treatment (excluded from analyses regarding neutropenia on day 36), and 2 Ph + ALL patients received nonhigh-risk induction treatment with Imatinib from day 15.